VIC Regimen Versus Bevacizumab Plus Chemotherapy as First-Line Treatment for BRAF V600E-Mutated Advanced Colorectal Cancer

Inclusion Criteria: * Age ≥ 18 and ≤80 years old * Histologically confirmed colorectal adenocarcinoma * Histologically confirmed BRAFV600E mutated and RAS wild-type * Initially unresectable metastatic or local CRC * ECOG performance status of 0-1 and life expectancy ≥3 months * adequate hepatic, renal, and hematologic function Exclusion Criteria: * Previously taken any targeted therapy, chemotherapy, intervention therapy, or radiotherapy for CRC within 6 months * Other cancers (with the exception of cervical cancer in situ and squamous cell carcinoma of the skin) within the previous 5 years.